FDA Plans Behind-The-Counter Meeting, Mulls “Transitional” Status
Executive Summary
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders
You may also be interested in...
BTC Class Might Not Happen Soon But FDA Working On Specific Proposal
Stakeholders in the concept of creating a behind-the-counter status for some drugs are at loggerheads on the need for a BTC class but agree on one point - FDA will need a long time to reach a decision on the issue
BTC Class Might Not Happen Soon But FDA Working On Specific Proposal
Stakeholders in the concept of creating a behind-the-counter status for some drugs are at loggerheads on the need for a BTC class but agree on one point - FDA will need a long time to reach a decision on the issue
FDA Open To Behind-The-Counter NDAs While Mulling “Continuum” Class
FDA is open to behind-the-counter switch applications in which companies propose innovative methods to solve access or selection issues, according to Office of Nonprescription Products staff